Navigation Links
Most Leukemia Patients Recover From 'Chemo Brain' After Transplant: Study
Date:5/6/2011

FRIDAY, May 6 (HealthDay News) -- A decline in memory and fine-motor skills is common among patients who undergo a bone marrow or stem cell transplant to treat leukemia or lymphoma, but most patients return to normal within five years, according to a new study.

Previous research has shown that the chemotherapy drugs these patients take before transplantation and medicines they take to prevent rejection of the transplanted cells can affect memory and motor skills. This study looked at how long it takes them to recover from those problems, often referred to as "chemo brain."

The study included 92 patients with chronic myeloid leukemia, acute leukemia, lymphoma or myelodysplastic syndrome, in which the bone marrow does not function normally. The patients had received an allogeneic (cells donated by another person) bone marrow or stem cell transplant.

After treatment, the patients' memory and motor skills were assessed. Most patients showed substantial improvement in neurocognitive function between one and five years after their transplant.

But deficits, described as mostly mild, persisted for five years in nearly 42 percent of the patients, a finding that surprised the researchers at the Fred Hutchinson Cancer Research Center in Seattle.

"We really thought the rates would be lower," study leader Karen Syrjala, director of Biobehavioral Sciences, said in a Hutchinson news release. "We were thrilled to see that people recovered substantially, but we also were surprised that so many people did continue to have measurable deficits in some areas even after five years."

Further research is needed to identify the reasons for these persistent deficits, she added.

The study was published May 2 online in the Journal of Clinical Oncology.

More information

The U.S. National Heart, Lung, and Blood Institute has more about bone marrow and stem cell transplant.

-- Robert Preidt

SOURCE: Fred Hutchinson Cancer Research Center, news release, May 3, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Agent selectively targets malignant B cells in chronic leukemia, study shows
2. Possible new approach to treating deadly leukemia in babies
3. New drug shows potential for treatment-resistant leukemia
4. ASH partners with AMEH and National Cancer Institute to improve diagnosis of leukemia in Mexico
5. Tracking down the origin of leukemia relapse
6. New approach to leukemia chemotherapy -- is a cure in sight?
7. UCSF researchers identify promising new treatment for childhood leukemia
8. Study reveals no impact of age on outcome in chronic myeloid leukemia patients treated with imatinib
9. Leukemia Patients Taking Gleevec Achieve Normal Death Rate
10. Less Is More With Acute Myeloid Leukemia Drug
11. When leukemia returns, gene that mediates response to key drug often mutated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® ... no longer use or need, from clothes to couches to dressers and bicycles. Roadie ... take them to the nearest Goodwill donation center through February 28th. , “January ...
(Date:1/20/2017)... ... 20, 2017 , ... Doctor C LLC, a company based out of Arizona ... to continue the marketing and distribution of its product, The Right C. , The ... better absorption than traditional vitamin C supplements. At the trade show, Doctor C had ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, ... everyday lives, recently attended the January ECRM Trade Show in Hilton Head, SC, ... for its large range of supplements that keep the body functioning at its ...
(Date:1/20/2017)... Viejo, California (PRWEB) , ... January 20, 2017 , ... ... easy to use inside of Final Cut Pro X," said Christina Austin - CEO ... on the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and earnest tale ... each of his children. “The Angel” is the creation of published author, Marjorie Lund-Fontaine, ... City, and impassioned writer. , When asked of her new book, Marjorie says, “‘The ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017 ARMO BioSciences, Inc., ... data on the Company,s lead investigational immuno-oncology drug AM0010 ... by the American Society of Clinical Oncology (ASCO), taking ... CA. "AM0010 induces the ... + T cells in the blood and tumors ...
(Date:1/21/2017)... -- Research and Markets has announced the addition of ... Route Of Administration, End User - Forecast to 2025" report ... ... a CAGR of around 7.8% over the next decade to reach ... analyzes the global markets for Advanced Drug Delivery across all the ...
(Date:1/20/2017)... , Jan 20, 2017 Research and ... Market By Type ([CBC, HGB/HCT, BMP, BUN Creatinine, Electrolyte Testing, HbA1c ... End-use, And Segment Forecasts, 2013 - 2024" report to their ... The ... billion by 2024 Introduction of innovative solutions on the ...
Breaking Medicine Technology: